alexa Hyaluronic Acid Mediated Enrichment of CD44 Expressing Glioblastoma Stem Cells in U251MG Xenograft Mouse Model | Open Access Journals
ISSN: 2157-7633
Journal of Stem Cell Research & Therapy
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Hyaluronic Acid Mediated Enrichment of CD44 Expressing Glioblastoma Stem Cells in U251MG Xenograft Mouse Model

Arun Vaidyanath#, Hafizah Binti Mahmud#, Apriliana Cahya Khayrani, Aung KoKo Oo, Akimasa Seno, Mami Asakura, Tomonari Kasai* and Masaharu Seno

Department of Medical Bioengineering Science, Okayama University, Japan

#These authors have contributed equally to the article

Corresponding Author:
Tomonari Kasai
Laboratory of Nano-Biotechnology
Department of Medical Bioengineering Science
Faculty of Engineering, Graduate School of Natural Science and Biotechnology
Okayama University, 3.1.1 Tsushima-Naka, Kita-ku, Okayama 700-8530, Japan
Tel: +81-86-251-8265
E-mail: t-kasai@okayama-u.ac.jp

Received Date: March 20, 2017; Accepted Date: April 03, 2017; Published Date: April 10, 2017

Citation: Vaidyanath A, Mahmud HB, Khayrani AC, Oo AKK, Seno A, et al. (2017) Hyaluronic Acid Mediated Enrichment of CD44 Expressing Glioblastoma Stem Cells in U251MG Xenograft Mouse Model. J Stem Cell Res Ther 7:384. doi:10.4172/2157-7633.1000384

Copyright: © 2017 Vaidyanath A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Stem Cell Research & Therapy

Abstract

Background: Glioblastoma is one of the most aggressive cancer with high mortality rates and poses several hurdles in the efficient chemotherapeutic intervention. Similar to other cancers, glioma also harbors CSCs, that are self-renewable, multipotent cells, which initiate the cancer incidence, chemotherapeutic resistance and cancer recurrence. The microenvironmental regulation in the brain tumor and metastasis involves the cooperative interaction between HA and CD44. CD44, being a multifaceted transmembrane glycoprotein by itself, or in combination with several other cell surface receptors, has been used as a marker for CSC isolation.

Methods: We established both adherent and nonadherent culture of U251MG cells by treating with high molecular weight HA. Further these cells were transplanted subcutaneously in Balb/c mouse for the generation of the xenograft model for the cancer stem cell. The tumor was further characterized for the establishment of the working model for molecular targeting studies of cancer stem cells.

Results: Here we showed the enrichment of the CD44 expressing population of glioblastoma cells by induction with hyaluronic acid. The non-adherent culture spheroids of U251MG cells showed up regulation in the CD44 expression along with aberrant activation of principal pluripotency genes OCT3/4, SOX2, KLF4 and Nanog. Using the HA-treated spheroid, we established an experimental xenograft mouse model with high angiogenesis enhanced tumor-initiating capacity while retaining the glioblastoma traits.

Conclusion: We characterized a mouse xenograft model of U251MG cells which could be a promising model system to study the molecular targeting approaches against CSCs in glioblastoma.

Keywords

HA; CD44; Cancer stem cell; Xenograft; Mouse model

Introduction

Glioblastoma multiforme is the one of the most malignant cancer affecting the brain making them one of the incurable cancers with a survival rate of 5%. Several studies have shed light on the cytogenetic, molecular and epigenetic alterations during its incidence and have characterized the tumor to its molecular level [1]. Histopathological attributes have helped in the classifying gliomas into two broad lineages: astrocytoma and oligodendroma and four grades (I-IV) of which the grade I and II corresponds to the low-grade glioma and III and IV correspond to the high-grade gliomas [2]. Glioblastoma cells are noninvasive outside the brain partly because of the effective blood brain barrier and the multitude of the complex microenvironment which it requires for the metastasis [3]. With the progression of the tumor metastatic cells uses the neovascularization for the spread of cancer and the blood-brain barrier changes to a blood-tumor barrier. Considering the microenvironment in the brain and its relative complexity in targeting the blood-tumor barrier are less receptive to chemotherapeutic intervention [4]. Glioma, like other cancers, are highly heterogeneous and shows hierarchy in their progression with the apex being the Cancer Stem Cell (CSCs) which repopulates the whole of the tumor. The CSCs are believed to be the primordial reason for the recurrence and reinstatement of the tumor after chemotherapeutic intervention and surgery as they are radiation and chemotherapeutic resistant [5]. The perpetual selfrenewability of the CSC is a complex process, which is mediated by the cellular and soluble attributes of the tumor microenvironment which includes the extracellular matrix, mesenchymal cells, endothelial cells and secretory molecules comprising cytokines and growth factor. The microenvironments surrounding the CSCs are termed as niche which modulates the cellular fate of the CSC [5-7].

CD44 is a multifunctional transmembrane glycoprotein which is a commonly used marker for isolating the CSCs from various cancers and mediating cell-cell and cell-matrix interactions furthering the malignancy and cancer dissemination. CD44 is typically associated with CD24, CD133, and CD34 for the enrichment of the various cancers. Hyaluronic Acid (HA) biosynthesis in the tumor microenvironment has been shown to increase the cancer aggressiveness and poor clinical outcome affecting the overall survival rate of the patients [8,9]. Our previous study with our platform of microarray method showed that the CD44 is overexpressed in several of the glioma cancer cells analyzed [10]. In breast cancer cells, HA overexpression drives EMT which is one of the key aspects of the CSC generation and propagation [11]. Over recent years CD44 along with other cell surface markers like CD133, CD90, CD24, ALDH, Nestin, EpCAM, and CD34 are also associated with CSC isolation and enrichment in various tumors [12]. In addition to its naturally occurring ligand, CD44 interacts with several ECM molecules including fibronectin galectin-8, laminin, fibrinogen, chondroitin sulfate [13], and osteopontin [14].

Targeted delivery of the chemotherapeutic compounds to the CSCs will be beneficial for the regression and recurrence of cancer. In this report, we are analyzing the enrichment of CD44 expression in spheroid culture with the addition of HA. Utilizing the spheroid culture, we developed a mouse glioblastoma tumor model for targeted drug delivery approaches for CSCs.

Materials and Methods

Cell culture

U251MG, SK-OV-3, and A172 were cultured as per the protocol described elsewhere [10]. For primary cultures mouse xenografts were cut into small pieces of 1 mm3 in HBSS. The tissues were further washed three times and were transferred to a 15-ml conical tube with 0.25% trypsin (3-4 fold) for 30 min at 37°C and were stopped by the addition of media containing FBS. The cell suspension was spun down at 800 rpm for 10 min. The cell pellet was washed with HBSS and was suspended in complete media and seeded into a dish at a density of 5-6 × 105/ml. Cells were passaged every 3 days and cells morphology was observed and photographed using Olympus IX81 (Olympus, Japan) microscope equipped with a light fluorescence device

Sphere formation and HA treatment

For the sphere formation assay, the cell number were adjusted to 1 × 104/ml and were cultured in ultra-low attachment dishes in the media devoid of FBS and containing Insulin/Transferrin/Selenium-X (ITS-X) and 100 μg/ml HA. The media without the supplementation of HA were included as a control. The cells were continued culturing for another 4 days and the spheres were disrupted to form secondary spheres for an additional culturing of 2 days. Spheres reaching 100 μm were considered as self-renewing and were used for the all the analysis.

Mouse

The nude mice (Balb/c-nu/nu, female, 4 weeks old) were obtained from Charles River, Japan. For all the transplantation studies, 1 × 106 cells were suspended in 200 μL in complete media and were injected subcutaneously and intra dermally. Size and volume measurement were done every 3-4 days with the following formula 0.5 × width 2 × length, in which width is the smallest diameter and length is the longest diameter. After 5 weeks, tumors were extracted and separated in 4 equal parts that were used for the primary cell culture, histological analysis as described below. The animals were maintained in dedicated animal facility in Okayama University and were fed ad libitum. All the animal experiments conducted were carefully designed and executed as per the general guidelines stipulated by the ethics committee of Okayama University.

RNA extraction and qRT PCR

RNA extraction and quantitative PCR were performed as described elsewhere [10]. The primers used for the detect the cDNAs of interest are tabulated in Supplementary Table 1.

Cell lysis and western blotting

Total cell extracts were collected as follows: Cells were lysed in 300 μl of lysis buffer (10 mM Tris-HCl, pH 7.5, 5 mM EDTA, 150 mM NaCl, 1% Triton-X 100, 10%(v/v) glycerol containing protease inhibitor cocktail for 30 min at 4°C. The lysate was then sonicated for 30 secs; 2 times and were centrifuged at 14,000 rpm for 10 min at 4°C and the supernatant were collected for the subsequent analysis. Cell extracts isolated were then subsequently separated in polyacrylamide gels, transferred onto PVDF membrane and incubated with specific antibodies as indicated. Immunoreactivity was revealed by chemiluminescense as per the manufacturer’s instruction and measured using the Atto imaging system (Atto, Japan).

Immunohistochemistry and histological analysis

The tumor extracted from the animal were primarily fixed with paraformaldehyde for 24 hrs followed by paraffin embedding procedure for histochemical analysis. The fixed tissue was then thoroughly washed and were permeated with increasing concentration of sucrose. Tissue blocks were made with OCT reagent (Sakura-Finetek, Netherlands) and were stored at -80°C until processing. The samples were fixed with absolute methanol for 10 min followed by blocking of the endogenous peroxidase with 3% H2O2 for 10 min. Using the Ellite anti-rabbit ABC vectastain kit (Vector Laboratories, USA) anti-CD31 (1:100, #ab28364, Abcam, UK), anti-CD133 (Novus Bio, USA) anti-LYVE-1 (Abcam, UK) antibodies were incubated for 2 hrs at room temperature. Immunoreactivity were detected by using DAB following the manufacturer’s recommendations. Images of the sections were processed with the FSX100 (Olympus, Japan) microscope for analysis and identification of the tumor type.

Results and Discussion

HA mediates enrichment of CD44 expressing population

High molecular weight HA stimulates the CD44 mediated clustering of breast cancer cells [15]. The CD44 binding to HA also has various outcomes based on the size of HA binding to CD44 such as proangiogenic and pro-inflammatory while nHA promoted anti-angiogenic and anti-inflammatory effects [16-18]. To assess the HA mediated enrichment of CD44, we cultured A172 and U251MG glioblastoma cells in both adherent and non-adherent conditions at a concentration of 100 μg/ml of HA. The cells in the adherent conditions without HA were bound to the plate while the spheroid formation could be seen with the non-adherent HA+ treated cells. Primary cultures (U251MG-P1) from the tumor-bearing mouse showed enrichment of more spheroid forming population when compared with the parental cell line (Figure 1A). The increment in the spheroid formation was further confirmed with culturing the A172, U251MG and U251MG-P1with (HA+) and without (HA-) the addition of HA in the culture medium (Figure 1B). The sphere formation was enhanced in U251MG-P1 resembling the stem cell morphology, while the parental cell line showed loosely formed aggregates with more differentiated cells.

stem-cell-research-therapy-Cell-Morphology

Figure 1: Induction of U251MG cells with HA. (A) Cell morphology of A172, U251MG and U251MG-P1 cells. Cells were cultured in culture dish with (100 μg/ml HA) and without HA in non-adherent conditions. Inset shows the magnified image of the spheroid formation in HA+ dish. (B). Spheroid formation of A172, U251MG, U251MG-P1 cells in the presence or absence of HA for 2 weeks. (C) Cell Morphology of A172, U251MG and primary culture of U251MG (U251MG-P1) after dissociation and culturing with HA for 2 weeks in adherent conditions.

To test the self-renewal in the tumor spheroids generated by the treatment, we dissociated the cells to single cells suspension with collagenase treatment and were cultured for 2 weeks with HA in adherent conditions (Figure 1C). The cells retained the spheroid forming ability which resembles that of the CSCs. The presence of HA-CD44 interaction in the cells promotes the aggregation and the CD44 over expressing population should be the reason for the reconstitution of the spheroid formation. The spheroid formation and the incidence time for the sphere formation were up regulated with the treatment of HA.

CD44 expression is upregulated by HA

We next checked the expression of CD44 in A172, U251MG and U251MG-P1 cell lines by qPCR. The expression analysis was done between the cell lines treated with HA+ and HA- and between the adherent culture and non-adherent culture. In U251MG and A172 cell lines the CD44 expression was up regulated 3 folds in non-adherent HA+ cells when compared with adherent HA-counterpart (Figure 2A and 2B). Similar results were obtained between U251MG and U251MG-P1 cells were the up regulation were found to be 2-fold when compared with adherent HA- conditions. The gene expression was further checked in the protein expression level through immunoblots with the cells. The immunoblot results clearly show that the HA-treated cells express more CD44 when compared to non-treated samples (Figure 2C). We further compared the enrichment of the CD44 expression in the population of cells U251MG and U251MG-P1 in the adherent and spheroid conditions with and without the induction of HA. All our results from these experiments proved that the CD44 expression is considerably up regulated by the treatment with HA there by the enrichment of the CD44 expressing population (Figure 2D). We further analyzed the effect of CD44 isoform expression in U251MG and U251MG-P1 cells. We found the expression of stable, V4, V8, V10 and V8-10 to be up-regulated in U251MG-P1 (Figure 2E).

stem-cell-research-therapy-Up-regulation

Figure 2: Up regulation of CD44 expression in U251MG cells. CD44 expression of adherent HA- and nonadherent HA+ treatment of U251MG (A) and A172 (B) by qPCR. Protein expression was further confirmed with the various treatment in A172 and U251MG cells A: Adherent, N: Non-adherent, H: Non-adherent HA+ (C). U251MG and U251MG-P1 cells were cultured under adherent and nonadherent conditions with or without the supplementation of HA. qPCR was performed and relative expression fold of CD44 was calculated (E) Quantitative PCR analysis of the expression of CD44 isoforms in U251MG and U251MG-P1 cells in adherent conditions. The data depicted are generated from two independent experiments. p values were calculated by Tukey HSD analysis (**p<0.01; *** p<0.001; n=2).

HA induces the expression of pluripotent genes

Aberrant activation of the pluripotent genes augments cancer initiation, progression, and chemotherapeutic resistance. These transcription factors are found to be over-expressed in several of the cancers and were used to identify cancer stem cell-like cells in glioblastoma [19]. HA-CD44 interaction was proved to activate Nanog which is principally [20] involved in the stem cell maintenance and self-renewal in the ES cells [21,22]. The activation of CD44 through the PKCε phosphorylates Nanog, with or without the association of Stat3 regulates the expression of other pluripotent, tumorigenic and multidrug resistance genes [21]. Nanog has shown to regulate the expression of Sox2, Oct3/4, and Rex1, the prominent pluripotent transcription factors during embryonic stem cell pluripotency. To assess the activation of embryonic pluripotency genes we performed the qPCR for the various treatment of the cells in the conditions depicted in Figure 3. The cells treated with HA augments the expression of pluripotency genes suggesting the possible acquiring of stem cell characteristics (Figure 3A). Since Sox2 has been proved to be the principal pluripotency genes in the generation of CSC we analyzed the expression further with immunoblots (Figure 3B).

stem-cell-research-therapy-pluripotent-genes

Figure 3: Expression of pluripotent genes in U251MG and U251M-P1 cells. (A) Cells were cultured with or without HA in adherent or nonadherent conditions. qPCR analysis was performed with the primers for Sox2, Oct3/4, Klf4 and Nanog. Error bars represents the mean SD of two independent experiments. Data are the mean of independent experiments and the p values were calculated by Tukey HSD analysis (* p<0.05; **p<0.01; n=3) (B) Cells cultured under the different conditions were lysed, separated on SDS-PAGE and were immunoblotted for Sox2 expression. The normalized relative band intensity was calculated from the blot and were plotted as a graph using Image J.

Generation of glioblastoma mouse model

Using the HA-induced CD44 up regulation we developed a glioblastoma mouse CSC model. We injected the spheres cultured in the presence of HA into the mouse subcutaneously. The tumor incidence time was faster in the treated spheres within 40 days when the adherent culture injected mouse showed no signs of tumor formation substantiating tumor-initiating population in the HA cultured spheroids. HA-treated spheroids generated tumors faster in the mouse by several folds when compared with the cultures of U251MG cells cultured without HA in adherent conditions. Thus, the CD44 induction with the non-adherent conditions is found to be the deciding factor for the reduced tumor latency in the mouse in question. We also assessed the tumor volume and the weight of the animal throughout the procedure. With the increment in the tumor volume, the weight of the animal remained within the acceptable range of 5% difference between the groups, when compared to the control (Figure 4). To evaluate the extent of differentiation in these tumors we also analyzed the Glial Fibrillary Acidic Protein (GFAP), a marker used to distinguish astrocytes from glial cells which also is a progenitor marker for the Neural Stem Cells (NSCs). In our hands, the GFAP expression is reduced in the U251MG-P1 cells which might be due to the enrichment of the undifferentiated stem-like the population in the primary tumor from the mouse (Supplementary Figure 1A). To further probe the stability of the GFAP expression in the tumor we subsequently retransplanted the tumor to the mice and were further confirmed with the western blot (Supplementary Figure 1A). Immunohistochemical analysis showed the extent of angiogenesis induction along with the presence of CD133+ cells intercalated throughout the tumor. We further probed for the expression of LYVE- 1 to check the lymphangiogenesis in the tumor and in our hands, the LYVE-1 expression was very much limited in the tumor (Supplementary Figure 1B). Histopathological and gene expression analysis have further confirmed the similar characteristic of the parental cancer cell line.

stem-cell-research-therapy-Characterization

Figure 4: Characterization of mouse model of glioma. (A) Tumor formation in mouse with U251MG spheroids treated with HA and adherent culture of U251MG without the HA treatment. (B) Tumor incidence rate with spheroid/HA+ and adherent/HA- cultures of U251MG cells; n=2.

Similar studies have been conducted in breast and colon cancer previously [23,24] along with combining the genetic model with xenograft transplantations [25]. Similar studies has shown that the CD133+ conditioned media in glioma enhances the angiogenesis in patient xenografts in mouse by elevated VEGF expression and endothelial differentiation thereby the presence of stem cell populations determines the key events in angiogenesis and vascular mimicry [26-28]. Similar model system was generated using miPS cells by our group where the angiogenesis/vascular mimicry were a cooperative interaction between the CSC and the microenvironment comprising of the differentiated populations, including the endothelial cells, and tumor stroma [29].

Activation of NFκB signaling in U251MG-P1 cells

NFκB complex activates MMP-9 and several other genes which are key response elements in the tumorigenesis and stem cell maintenance through tumor microenvironment mediated inflammation and ECM signaling [30-32]. To test the activation of inflammatory mediators we checked the NFκB activation in the HA-treated spheroids. NFκB activation has been associated with the mesenchymal subtype of the glioma and is proved to provide radioresistance in cancer [33]. We found that the HA induces p50/105 activation in the U251MG-P1 cells consistent with the results got from the high-grade glioblastoma models. Further, we found that p65 is activated in both parental and U251MG-P1 cells. Based on these observations we then checked for the genes involved in the NFκB family by quantitative PCR and we found that the NFKB1, which is essential for the translocation of the p50/65 complex into the nucleus for the gene regulation, was suppressed, and REL-B was found to be expressing in the U251MG-P1 cells showing the mesenchymal nature of the primary tumor cells [34] (Supplementary Figure 2).

Conclusion

Xenograft models give more simultaneity and reproducibility with their high incidence of the tumor formation Also they allow easy tumor visualization for the drug development process and efficient penetrance of the drug interactions with the tumor [35,36]. Further the establishment of the model system will be advantageous for the replenishment of CSC, as in long turn in vitro culture system these cells undergo differentiation to normal cancer cells. Enrichment of CD44 expressing cells would be a better platform in the drug targeting experiments for CSCs as we previously successfully showed targeting HER2 breast cancer cells with our bionanocapsule [37] and liposome [38,39] with HER2-binding artificial ligands and such models will provide extensive knowledge in the therapeutic intervention in curbing the cancer growth and metastasis. The advantage of our model involves its cost-effective enrichment of the CD44 expressing glioblastoma cells and high tumor incidence within a short time, enables us to study the effect of chemotherapeutic targeting. Further, the development of the mouse model will assist in the molecular targeting using anti-CD44 antibody-drug encapsulated nanoparticles for glioma CSCs.

Acknowledgements

This research was supported by the Grant-in-Aid for Scientific Research (A) No. 25242045 (MS); the Grant-in-Aid for Challenging Exploratory Research No. 26640079 (MS); the Japan Science and Technology Agency, Matching Planner Program-Tansaku Shiken-Grant (TK) and Wesco Scientific Promotion Foundation (TK). Authors appreciate Dr. Akifumi Mizutani for his guidance and support.

Conflict of Interest

All the authors declare no competing financial interest.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 144
  • [From(publication date):
    April-2017 - May 25, 2017]
  • Breakdown by view type
  • HTML page views : 117
  • PDF downloads :27
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

agrifoodaquavet@omicsonline.com

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

clinical_biochem@omicsonline.com

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

business@omicsonline.com

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

chemicaleng_chemistry@omicsonline.com

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

environmentalsci@omicsonline.com

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

engineering@omicsonline.com

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

generalsci_healthcare@omicsonline.com

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

genetics_molbio@omicsonline.com

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

immuno_microbio@omicsonline.com

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

omics@omicsonline.com

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

materialsci@omicsonline.com

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

mathematics_physics@omicsonline.com

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

medical@omicsonline.com

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

neuro_psychology@omicsonline.com

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

pharma@omicsonline.com

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

social_politicalsci@omicsonline.com

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version